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ABSTRACT 
Objective: To improve the parent strain of Variovorax paradoxus for the production of methotrexate (MTX) degrading enzyme and to study the 
serum stability, release kinetics and functionality of the nano complexes of the enzyme with human serum albumin (HSA) 
Methods: The activity of the enzyme was quantified by using the extinction coefficient of 8300 for the substrate, MTX. The mutant strain of V. 
paradoxus was isolated by exposing the cells to the UV light (302 nm) so that 50 % of the cells were killed. The enzyme was purified on DEAE-
cellulose, and sephadex-G-100 columns and the purity of the enzyme was checked on 10 % SDS-polyacrylamide gel. The enzyme-HSA nano 
complexes were prepared by adopting desolvation-crosslinking method and their size was determined by using transmission electron 
microscope.  
Results: MTX degrading enzymes are required to avoid the toxicity of the MTX during the treatment of cancer. The enzyme from V. paradoxus 
converts the MTX into non-toxic glutamate and 4-amino-N [10]-methylpteroate, and the culture utilizes the derived glutamate. Improving the 
production of this enzyme will be beneficial due to its therapeutic application. Different carbon and nitrogen sources didn’t improve the production 
of this enzyme from the parent strain of M. verrucaria. The strain improvement was carried out by using UV radiation to improve the yields of the 
enzyme. The mutant strain produced around 6 times higher levels of the enzyme compared to the parent suggesting its advantage for the industrial 
production of the enzyme. Since this enzyme is of microbial origin, it was complexed to the safe carrier, HSA and these complexes showed their size 
in the nano-range. The nano complexes showed longer stability compared to the native enzyme in the serum, and the enzyme was readily released 
from the complex suggesting the protective role of the carrier, HSA. The nano complexes showed the higher degradation of MTX in the serum 
compared to the native enzyme suggesting their better functionality compared to the native enzyme. 
Conclusion: Usage of mutant strain will be advantageous for the industrial production of the enzyme since it produces higher levels of enzyme 
compared to the parent strain. Enzyme-HSA nanocomputers will be a better choice for the therapeutic applications since they show better serum 
stability and functionality compared to the native enzyme. 
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INTRODUCTION 
MTX (4-amino-N [10]-methylpteroyl-L-glutamate) is an antagonist 
of folic acid and it has been used widely as a chemotherapeutic 
agent. Choriocarcinoma and Burkitt's lymphoma were treated by 
using MTX [1]. Usage of a high dose of MTX for the treatment of 
cancers will harm normal cells and leads to the toxicity, and it kills 
the cells by inhibiting the synthesis of DNA. This life-threatening 
toxicity is not avoidable with the available reagent leucovorin if 
there is a kidney failure in the patient. The enzymes that degrade 
MTX into the inactive components will be beneficial in this context. 
Enzymes that degrade MTX were reported from few microbial 
species [1-5]. However, these enzymes were not explored for 
therapeutic applications except carboxypeptidase G2
MATERIALS AND METHODS 
 [6, 7]. In the 
present study, the carboxypeptidase G that was reported long back 
[2] was explored since this enzyme was not completely 
characterized and explored for the therapeutic applications. The 
organism that produces this enzyme was not thoroughly exploited 
for the production of the enzyme. Hence, the studies that improve 
the production of this enzyme will benefit the pharma and biotech 
industries. In this study, different carbon and nitrogen sources were 
evaluated for the economic production of carboxypeptidase G in 
addition to carrying out the strain improvement of V. paradoxus. 
Since this enzyme is from the microbial source, it causes 
immunotoxicity if delivered directly into the system. Hence, in the 
present investigation, studies were carried out for complexing this 
enzyme with the safe nanocarrier, HSA and the nano complexes 
were evaluated in vitro for their functionality.  
Microbial cultures and reagents 
The parent microbial culture was obtained from American type 
culture collection, USA and maintained on the agar slants containing 
folic acid (0.1%), KH₂PO₄ (0.05%), K₂HPO₄.3H₂O (0.12%) and 
solutions of salt A (MgSO₄.7H₂O, 1%; CaCl₂.2H₂O, 0.1%; FeSO₄.7H₂O, 
0.1%) and salt B (MnSO₄, 0.1%; Na₂MoO₄, 0.1%). This culture was 
initially deposited as Pseudomonas sp (2, 3) and subsequently 
renamed as V. paradoxus (ATCC 25301). The submerged culture was 
grown in the folic acid medium containing the above components for 
the production of the enzyme. MTX was procured from Sisco 
Research Laboratories, Mumbai, India and human serum was 
obtained from Sigma-Aldrich.  
Enzyme assays 
Enzyme activity on the MTX was assayed by using 100 µl of 
appropriately diluted cell lysate or purified enzyme. The reaction 
was started by adding the enzyme to the mixture containing MTX 
(300 µmol) & ZnSO4
The total reaction volume was 3.5 ml and it was buffered with Tris-HCl 
(0.1 mol, pH 7.4). The enzyme activity was quantified by using an 
extinction coefficient of 8300 for MTX. One unit corresponds to the 
amount of enzyme required to hydrolyze the 1 µmol of MTX per min.  
 (0.2 mmol) at 37 °C and decrease in the 
absorbance was measured at 320 nm by using UV-Vis double beam 
spectrophotometer (Shimadzu, 1800).  
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To find out the stability of the enzyme either native enzyme or its 
HSA nano complexes were incubated with human serum at 37 °C 
and 50 rpm. Then samples were withdrawn at different points of 
time and assayed for the enzyme activity as described above. The 
release of enzyme from the enzyme-HSA nanocomplexes was 
studied in vitro by incubating the nanocomplexes with human serum 
at 37 °C and 50 rpm. At different time intervals, the serum was 
withdrawn, and nanocomplexes were pelleted by centrifuging at 
10,000 rpm and 4 °C for 20 min and the released enzyme present 
in the supernatant was assayed on the MTX. The functionality of 
the nanocomplexes or native enzyme was studied in vitro by 
incubating either one of them with MTX (300 µM) containing 
human serum at 37 °C and 50 rpm. At different periods of time, the 
MTX present in the serum was monitored by measuring the optical 
density at 320 nm. 
Isolation of the mutant 
The parent strain of V. paradoxus was grown to the OD of 0.5 (at 578 
nm) in the folic acid (0.1%) medium containing different salts. Then 
bacterial cells were diluted 1:10 and plated on the folic acid agar 
plates and exposed to the UV light (302 nm) to get 50% killing. Later 
the plates were incubated overnight at 4 °C in the dark and 
thereafter at 26 °C for 24h. Survived colonies were picked onto the 
folic acid agar plates coated with MTX (0.1 mM) and incubated at 26 
°C for 24h. Emerged colonies were grown in the folic acid medium, 
and bacterial cell lysate was used for assaying the MTX degrading 
enzyme activity as described in the section ‘enzyme assays’. The 
mutants producing higher enzyme activity compared to the parent 
were repeatedly subcultured and the mutant that stably 
overproduced the enzyme was selected.  
Purification of the enzyme 
The mutant culture of V. paradoxus was grown on the folic acid 
medium at 26-30 °C and 150 rpm for 24 h. The grown culture was 
centrifuged at 5000 rpm and 4 °C for 20 min and the cell pellet was 
washed twice with Tris-HCl buffer (0.05 mol, pH 7.4, 0.2 mmol 
ZnSO4) and re-suspended in the same buffer containing 0.5 mmol 
EDTA and 0.2 mmol PMSF and sonicated (250 W, 30 KHz) on the ice. 
The cell suspension was centrifuged at 5000 rpm and 4 °C for 20 min 
and supernatant was precipitated with 80% ammonium sulphate at 
4 °C. The precipitated protein was dissolved into Tris-HCl buffer (0.1 
mol, pH 7.4) and dialyzed against the Tris-Acetate buffer (0.02 mol, 
pH 9.0) containing 0.2 mmol ZnSO4 to remove the ammonium 
sulphate. Then the sample was loaded on the DEAE-cellulose column 
equilibrated with Tris-Acetate buffer (0.02 mol, pH 9.0) containing 
0.2 mmol ZnSO4 and the bound enzyme was eluted with 0.2-1.0 mol 
NaCl prepared in the same buffer. Fractions showing the enzyme 
activity were mixed and concentrated by using lyophilizer after the 
dialysis. The sample was loaded on the Sephadex-G-100 column 
equilibrated with Tris-HCl buffer (0.05 mole, pH 7.4, 0.2 mM ZnSO4
Preparation of nano-complexes 
) 
and eluted with the same buffer. The fractions having the major 
enzyme activity were mixed and the purity of the enzyme was 
checked on the 10% SDS-polyacrylamide gel. The protein 
concentration was estimated by Bradford assay. 
The enzyme-HSA nano-complexes were prepared by the 
desolvation-crosslinking method as described earlier [8]. Briefly, the 
enzyme was mixed with HSA in the ratio of 1:25 in the 0.1 mol Tris-
HCl (pH 7.3, 0.2 mmol ZnSO4
Transmission electron microscopy 
) buffer containing 300 mM NaCl. The 
final protein concentration was 6 mg/ml. Four ml of acetone was 
added to the 1 ml of enzyme and HSA mixture (on the ice with mild 
stirring) drop by drop at the rate of 1 ml/min. Then 4 µl of 
glutaraldehyde (2.5 % in water) was added and continued the 
stirring for 20 min. The mixture was centrifuged at 1000 rpm and 4 
°C for 5 min and the supernatant was removed. The pellet was 
suspended in the required amount of buffer and sonicated for 1 sec 
(20 cycles, bath Sonicator, 100 W, 33 KHz) on ice. The sample was 
assayed for the activity of the enzyme on MTX as described above. 
Suspended enzyme-HSA nano-complexes were drop casted on the 
carbon coated copper grid by placing a drop of the sample and 
allowing it to air dry at room temperature for 2 h. The image was 
captured at the resolution of 500 nm by using FEI Technai 
Transmission Electron Microscope. Average size and shape of the 
nano-complexes were studied.  
RESULTS AND DISCUSSION 
The parent culture that produces MTX degrading enzyme was 
isolated from Rock Creek mud by the enrichment culture [2]. This 
organism can use MTX as a sole carbon and nitrogen source [2]. This 
enzyme showed peptidase activity, and it appears to have 
considerable specificity to the carboxy terminal glutamate or 
glutamine [3], accordingly this MTX degrading enzyme was named 
as carboxypeptidase G [3]. This enzyme converts MTX into non-toxic 
glutamate and 4-amino-N [10]-methylpteroate, and the parent 
culture utilizes the derived glutamate [2]. This parent culture didn’t 
show any growth on the carbon sources i.e. glucose, lactose, sucrose, 
maltose, glycerol and soluble starch and thereby there was no MTX 
degrading enzyme activity on these sources (table 1). However, 
parent strain could be able to grow on the folic acid, MTX and 
sodium glutamate and produced highest MTX degrading enzyme 
activity on the folic acid followed by sodium glutamate and MTX 
(table 1). When different nitrogen sources were added to the folic 
acid medium, the parent strain didn’t show any improvement in the 
production of the enzyme (table 2). Hence, folic acid itself is 
sufficient for the organism to produce the MTX degrading enzyme.  
 
Table 1: Effect of carbon sources on the production of MTX 
degrading enzyme by the parent strain of V. paradoxus 






Soluble starch 0 
Folic acid 0.168 
Methotrexate 0.067 
Sodium glutamate 0.086 
 
Table 2: Effect of addition of nitrogen sources to the folic acid 
medium on the production of MTX degrading enzyme by the 
parent strain of V. paradoxus 
Nitrogen source Activity (Units) 
Potato extract 0.170 
Corn steep liquor 0.198 
Peptone 0.151 
Soyapeptone 0.212 
Diammonium hydrogen phosphate 0.100 
Ammonium dihydrogen phosphate 0.156 
Ammonium nitrate 0.142 
Ammonium sulfate 0.179 
Ammonium chloride 0.103 
Tryptone 0.224 
Folic acid alone 0.229 
 
Physiological mutations have credible importance in the strain 
improvement for various fermentation processes. Hence, the strain 
improvement through the induced mutation is a regular practice in 
all industrial processes that use microbes. In all these studies, 
mutations were induced with ultraviolet rays, ionizing radiations 
and chemicals like lithium chloride, camphor, nitrous oxide, etc. 
Microbes were improved for the enzyme production by subjecting 
the spores to UV rays [9, 10]. However, microbes producing the 
therapeutic MTX degrading enzymes were not explored for the 
strain improvement. The mutations were induced into the parent 
strain of V. paradoxus by using UV radiation and the mutant (no. 
1068) that overproduces the MTX degrading enzyme was isolated as 
described in the materials and methods section. The mutant (1068) 
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produced around 6 times higher levels of MTX degrading enzyme 
compared to the parent in the folic acid medium after 20 h of 
fermentation (fig. 1) suggesting its advantage for the industrial 
production of the enzyme. When time course studies were 
conducted the parent showed the production of the enzyme at 12 h 
and it reached maximum at 18 h and almost no change thereafter 
(fig. 2). Mutant showed higher production of the enzyme compare to 
the parent at all time points (fig. 2). However, the mutant showed 
the highest production at 24 h and slight decrease afterwards (fig. 
2). Overproduction of the MTX degrading enzyme by the mutant at 
the same fermentation period will benefit the pharma industry. 
 
 
Fig. 1: Bar diagram showing the MTX degrading enzyme 




Fig. 2: Graph showing the time course studies on the production 
of MTX degrading enzyme by the parent and mutant strains of 
V. paradoxus 
 
Though the microbial enzymes are helpful during the therapy, they 
are foreign to the human body and raise an immune response when 
injected, which will limit their repeated administration. Another 
problem is their instability in the system. Hence, one has to evolve 
with safe and effective carriers for systemic administration of 
enzymes for therapeutic purposes. Non-viral vectors are 
advantageous since they will minimise the host immune response. 
Number of non-viral carriers, especially nanoparticle systems were 
developed using polymers like poly (D,L-lactic-co-glycolic acid) 
(PLGA) [11], chitosan [12], poly-L-lysine [13]; dendrimers like 
polypropylene imine [14] and lipids like ethyl dimyristoyl 
phosphatidylcholine [15], 1,2-distearyl oxy-N,N-dimethyl-3-
aminopropane [16], 1,2-dioleoyl-sn-glycero-3-trimethyl ammonium 
propane [17]. These delivery systems achieved moderate success 
due to the safety issues of the carrier materials. Among the above-
mentioned carriers, PLGA, the only material approved for the human 
application, was criticized for incomplete delivery [18], restricting 
the complete utilisation of therapeutic dose. Hence, new carrier 
systems have to be explored to overcome such problems and to 
achieve safe and efficient delivery.  
HSA remains a non-explored carrier for the delivery of the 
therapeutic enzymes even though it was approved for the parenteral 
use in humans. It is a 66 KDa protein and bind to different 
endogenous and exogenous molecules either covalently or 
reversibly with high affinity allowing it to serve as a transporter for 
various compounds [19]. Binding to HSA often results in the 
increased plasma solubility, reduced toxicity and increased the half-
life of the bound molecule in vivo [20]. Another study revealed that 
HSA nanoparticles sustained the in vitro release of superoxide 
dismutase gene over 6 d, stabilized it against degradation and 
caused no cytotoxicity in ARPE 19 cells [21]. Its endogenous nature 
renders HSA highly efficient and safe as a carrier for therapeutic 
enzyme delivery. Hence, in the current study, HSA was used as a 
carrier material in the nanoparticles for the delivery of the 
therapeutic MTX degrading enzyme from the mutant strain of V. 
paradoxus. 
The purified enzyme was used for the synthesis of enzyme-HSA 
nanocomplexes and they were prepared by adopting desolvation-
cross linking method as described in the ‘materials and methods’ 
section. The complexes were in a rectangular shape with the length 
and breadth around 400 and 500 nm (fig. 3) respectively suggesting 
their nano size. When enzyme-HSA nanocomplexes or native 
enzyme was incubated with human serum at 37 °C in vitro with mild 
shaking the native enzyme lost most of the activity after 2 h and 
complete activity after 4 h (fig. 4) suggesting its short stability in the 
serum, whereas, enzyme-HSA nanocomplexes retained their 
complete activity up to 8 h and most of their activity up to 20 h of 
incubation (fig. 4). This suggests the better stability of the enzyme-
HSA nanocomplexes in the serum compared to the native enzyme. 
This stability could be due to the protective effect of HSA since 
proteases present in the serum will degrade the enzyme. However, 
enzyme-HSA nanocomplexes lost their major activity after 24 h (fig. 4).  
 
 




Fig. 4: Graph showing the activity of the native enzyme and its 
HSA nanocomplexes when incubated with the human serum at 
37 °C for different periods of time 
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When the release of the enzyme from the enzyme-HSA 
nanocomplexes was studied in vitro by incubating the 
nanocomplexes with human serum around 80 % of the enzyme was 
released after 10 min and there was a complete release of the 
enzyme after 60 min (fig. 5) suggesting the loose binding of the 
majority of the enzyme to the HSA. The native enzyme could able to 
show significant degradation of the MTX-only after 30 min and there 
was no degradation after that (fig. 6, black bars) and this could be 
due to the degradation of the native enzyme by the proteases 
present in the serum. However, the enzyme-HSA nanocomplexes 
showed the significant degradation of the MTX just after the 5 min 
itself, and they degraded the MTX better than the native enzyme at 
all the points (fig. 6, grey bars) suggesting the protecting effect of the 
HSA on the enzyme in the nanocomplexes. 
 
 
Fig. 5: Bar diagram showing the % release of the enzyme from 
the enzyme-HSA nanocomplexes when incubated with the 
human serum at 37 °C & 50 rpm for different periods of time 
 
 
Fig. 6: Bar diagram showing the effect of native enzyme (black 
bars) or its HSA nanocomplexes (grey bars) on the MTX when 
they were incubated for different periods of time with the 
human serum containing MTX at 37 °C & 50 rpm 
 
CONCLUSION 
Due to the potential ability of the MTX degrading enzymes to 
overcome MTX toxicity increasing their production will definitely 
benefit the pharma sector. Strain improvement of the M. verrucaria 
was carried out to increase the production of MTX degrading 
enzyme since different carbon and nitrogen sources didn’t improve 
the production from the parent strain. Mutant produced significantly 
higher levels of enzyme compared to the parent, and hence, usage of 
mutant will be advantageous for the industrial production of the 
enzyme. Enzyme-HSA nanocomplxes showed better serum stability 
and functionality compared to the native enzyme suggesting their 
better suitability for the therapeutic applications. 
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